|
1
|
Davidovici BB, Sattar N, Prinz J, Puig L,
Emery P, Barker JN, van de Kerkhof P, Ståhle M, Nestle FO,
Girolomoni G and Krueger JG: Psoriasis and systemic inflammatory
diseases: Potential mechanistic links between skin disease and
co-morbid conditions. J Invest Dermatol. 130:1785–1796. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kölliker Frers RA, Bisoendial RJ, Montoya
SF, Kerzkerg E, Castilla R, Tak PP, Milei J and Capani F: Psoriasis
and cardiovascular risk: Immune-mediated crosstalk between
metabolic, vascular and autoimmune inflammation. IJC Metab Endocr.
6:43–54. 2015. View Article : Google Scholar
|
|
3
|
Sârbu MI, Georgescu SR, Tampa M, Sârbu AE
and Simionescu O: Biological therapies in psoriasis - revisited.
Rom J Intern Med. 56:75–84. 2018.PubMed/NCBI
|
|
4
|
Murari K, Ray AS and Lodha RS: Adenosine
deaminase: A potential biomarker for evaluating the severity of
psoriasis. Int J Pharma Bio Sci. 6:629–634. 2015.
|
|
5
|
Shree UGB, Vishal B, Shindhu M, Shenoy MM
and Shenoy C: Advanced oxidation protein product in psoriasis and
its correlation with disease severity. Int J Sci Stud. 2:156–159.
2015.
|
|
6
|
Basavaraj KH, Vasu Devaraju P and Rao KS:
Studies on serum 8-hydroxy guanosine (8-OHdG) as reliable biomarker
for psoriasis. J Eur Acad Dermatol Venereol. 27:655–657. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nwabudike LC and Tatu AL: Reply to Happle
R. And al. Koebners sheep in Wolf's clothing: Does the isotopic
response exist as a distinct phenomenon? J Eur Acad Dermatol
Venereol. 32:336–337. 2018.
|
|
8
|
Tampa M, Sarbu MI, Mitran MI, Mitran CI,
Matei C and Georgescu SR: The pathophysiological mechanisms and the
quest for biomarkers in psoriasis, a stress-related skin disease.
Dis Markers. 2018:58236842018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Căruntu C, Boda D, Căruntu A, Rotaru M,
Baderca F and Zurac S: In vivo imaging techniques for psoriatic
lesions. Rom J Morphol Embryol. 55:1191–1196. 2014.PubMed/NCBI
|
|
10
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI
|
|
11
|
Negrei C, Arsene AL, Toderescu CD, Boda D
and Ilie M: Acitretin treatment in psoriasis may influence the cell
membrane fluidity. Farmacia. 60:767–772. 2012.
|
|
12
|
Nicolae I, Ene CD, Schipor S, Tampa M,
Matei C and Georgescu SR: Dopamine-chemical mediator in atopic
dermatitis. Rev Chim. 64:1201–1206. 2013.
|
|
13
|
Negrei C, Ginghină O, Căruntu C, Burcea
Dragomiroiu GT, Jinescu GE and Boda DA: Investigation relevance of
methotrexate polyglutamates in biological systems by high
performance liquid chromatography. Rev Chim. 66:766–768. 2015.
|
|
14
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
|
|
15
|
Gisondi P, Galvan A, Idolazzi L and
Girolomoni G: Management of moderate to severe psoriasis in
patients with metabolic comorbidities. Front Med (Lausanne).
2:12015.PubMed/NCBI
|
|
16
|
Sarbu MI, Tampa M, Matei C, Mitran CI,
Mitran MI, Pituru S, Pop CS, Saramet G and Georgescu SR: Infliximab
biosimilar versus methotrexate for the treatment of moderate to
severe psoriasis. Farmacia. 65:962–967. 2017.
|
|
17
|
Wan J, Wang S, Haynes K, Denburg MR, Shin
DB and Gelfand JM: Risk of moderate to advanced kidney disease in
patients with psoriasis: Population based cohort study. BMJ. Oct
15–2013.(Epub ahead of print). doi:
https://doi.org/10.1136/bmj.f5961. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chi CC, Wang J, Chen YF, Wang SH, Chen FL
and Tung TH: Risk of incident chronic kidney disease and end-stage
renal disease in patients with psoriasis: A nationwide
population-based cohort study. J Dermatol Sci. 78:232–238. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Negrei C, Caruntu C, Ginghina O,
Dragomiroiu GT, Toderescu CD and Boda D: Qualitative and
quantitative determination of methotrexate polyglutamates in
erythrocytes by high performance liquid chromatography. Rev Chim.
66:607–610. 2015.
|
|
20
|
Sârbu MI, Tampa M, Mitran MI, Mitran CI,
Limbău AM and Georgescu SR: Adverse reactions of biological
therapies in patients with psoriasis. J Mind Med Sci. 4:4–12. 2017.
View Article : Google Scholar
|
|
21
|
Lisowska-Myjak B: Serum and urinary
biomarkers of acute kidney injury. Blood Purif. 29:357–365. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu HJ, Yen CH, Wu IW, Hsu KH, Chen CK,
Sun CY, Chou CC, Chen CY, Tsai CJ, Wu MS, et al: The association of
uremic toxins and inflammation in hemodialysis patients. PLoS One.
9:e1026912014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu G, Tu W and Qin S: The relationship
between deiodinase activity and inflammatory responses under the
stimulation of uremic toxins. J Transl Med. 12:2392014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Duranton F, Cohen G, De Smet R, Rodriguez
M, Jankowski J, Vanholder R and Argiles A: European Uremic Toxin
Work Group: Normal and pathologic concentrations of uremic toxins.
J Am Soc Nephrol. 23:1258–1270. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boueiz A, Damarla M and Hassoun PM:
Xanthine oxidoreductase in respiratory and cardiovascular
disorders. Am J Physiol Lung Cell Mol Physiol. 294:830–840. 2008.
View Article : Google Scholar
|
|
26
|
Lisowska-Myjak B and Skarżyńska E: Role of
uremic compounds in organ injury. J Nephrol Ther.
5:10002052015.
|
|
27
|
Lisowska-Myjak B: Uremic toxins and their
effects on multiple organ systems. Nephron Clin Pract. 128:303–311.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia JF, Liang QL, Hu P, Wang YM, Li P and
Luo GA: Correlations of six related purine metabolites and diabetic
nephropathy in Chinese type 2 diabetic patients. Clin Biochem.
42:215–220. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xia J, Wang Z and Zhang F: Association
between related purine metabolites and diabetic retinopathy in type
2 diabetic patients. Int J Endocrinol. Feb 13–2014.(Epub ahead of
print). doi: 10.1155/2014/651050. View Article : Google Scholar
|
|
30
|
Avci E, Cakir E, Cevher SC, Yaman H,
Agilli M and Bilgi C: Determination of oxidative stress and
cellular inflammation in patients with diabetic nephropathy and
non-diabetic nephropathy being administered hemodialysis treatment
due to chronic renal failure. Ren Fail. 36:767–773. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ishikawa T, Aw W and Kaneko K: Metabolic
interactions of purine derivatives with human ABC transporter
ABCG2: Genetic testing to assess gout risk. Pharmaceuticals
(Basel). 6:1347–1360. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dervisoglu E, Akturk AS, Yildiz K, Kiran R
and Yilmaz A: The spectrum of renal abnormalities in patients with
psoriasis. Int Urol Nephrol. 44:509–514. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Visconti L, Leonardi G, Buemi M, Santoro
D, Cernaro V, Ricciardi CA, Lacquaniti A and Coppolino G: Kidney
disease and psoriasis: Novel evidences beyond old concepts. Clin
Rheumatol. 35:297–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Boda D, Negrei C, Nicolescu F and Bălălău
CR: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
35
|
Kwon HH, Kwon IH, Choi JW and Youn JI:
Cross-sectional study on the correlation of serum UA with disease
severity in Korean patients with psoriasis. Clin Exp Dermatol.
36:473–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Christophers E and Mrowietz U: Psoriasis.
Fitzpatrick's dermatology in general medicine. Freedberg IM, Eisen
AS, Wolff K, Austen KF, Goldsmith LA and Katz SI: 1. 6th.
McGraw-Hill; New York, NY: pp. 407–427. 2003
|
|
37
|
Ataseven A, Kesli R, Kurtipek GS and
Ozturk P: Assessment of lipocalin 2, clusterin, soluble tumor
necrosis factor receptor-1, interleukin-6, homocysteine, and UA
levels in patients with psoriasis. Dis Markers. 2014.5417092014.
doi: 10.1155/2014/541709. PubMed/NCBI
|
|
38
|
Gisondi P, Targher G, Cagalli A and
Girolomoni G: Hyperuricemia in patients with chronic plaque
psoriasis. J Am Acad Dermatol. 70:127–130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ciragil P, Kurutas EB and Miraloglu M: New
markers: Urine xanthine oxidase and myeloperoxidase in the early
detection of urinary tract infection. Dis Markers. 2014.2693622014.
doi: org/10.1155/2014/269362. PubMed/NCBI
|
|
40
|
Vorbach C, Harrison R and Capecchi MR:
Xanthine oxidoreductase is central to the evolution and function of
the innate immune system. Trends Immunol. 24:512–517. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tampa M, Nicolae I, Ene CD, Sarbu I, Matei
C and Georgescu SR: Vitamin C and thiobarbitUA reactive substances
(Tbars) in psoriasis vulgaris related to psoriasis area severity
index (Pasi). Rev Chim. 68:43–47. 2017.
|
|
42
|
Matei C, Tampa M, Caruntu C, Ion RM,
Georgescu SR, Dumitrascu GR, Constantin C and Neagu M: Protein
microarray for complex apoptosis monitoring of dysplastic oral
keratinocytes in experimental photodynamic therapy. Biol Res.
47:332014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dinu LU, Ene CD, Nicolae IL, Tampa M,
Matei CL and Georgescu SR: The serum levels of
8-hidroxy-deoxyguanosine under the chemicals influence. Rev Chim.
65:1319–1326. 2014.
|
|
44
|
Barreto FC, Stinghen AE, de Oliveira RB,
Franco AT, Moreno AN, Barreto DV, Pecoits-Filho R, Drüeke TB and
Massy ZA: The quest for a better understanding of chronic kidney
disease complications: An update on uremic toxins. J Bras Nefrol.
36:221–235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Glorieux G and Tattersall J: Uraemic
toxins and new methods to control their accumulation: Game changers
for the concept of dialysis adequacy. Clin Kidney J. 8:353–362.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Semchyshyn HM: Reactive carbonyl species
in vivo. Generation and dual biological effects.
ScientificWorldJournal 2014. 4178422014.doi:
10.1155/2014/417842.
|
|
47
|
Sánchez-Lozada LG, Lanaspa MA,
Cristóbal-García M, García-Arroyo F, Soto V, Cruz-Robles D,
Nakagawa T, Yu MA, Kang DH and Johnson RJ: UA-induced endothelial
dysfunction is associated with mitochondrial alterations and
decreased intracellular ATP concentrations. Nephron, Exp Nephrol.
121:71–78. 2012. View Article : Google Scholar
|
|
48
|
Davidovici BB, Sattar N, Prinz J, Puig L,
Emery P, Barker JN, van de Kerkhof P, Ståhle M, Nestle FO,
Girolomoni G, et al: Psoriasis and systemic inflammatory diseases:
Potential mechanistic links between skin disease and co-morbid
conditions. J Invest Dermatol. 130:1785–1796. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim IY, Lee DW, Lee SB and Kwak IS: The
role of UA in kidney fibrosis: Experimental evidences for the
causal relationship. BioMed Res Int. 2014.6387322014. doi:
10.1155/2014/638732. PubMed/NCBI
|
|
50
|
Reiners JJ Jr and Rupp T: Conversion of
xanthine dehydrogenase to xanthine oxidase occurs during
keratinocyte differentiation: Modulation by
12-O-tetradecanoylphorbol-13-acetate. J Invest Dermatol.
93:132–135. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Deliconstantinos G, Villiotou V and
Stavrides JC: Alterations of nitric oxide synthase and xanthine
oxidase activities of human keratinocytes by ultraviolet B
radiation. Potential role for peroxynitrite in skin inflammation.
Biochem Pharmacol. 51:1727–1738. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Festugato M: Adenosine: An endogenous
mediator in the pathogenesis of psoriasis. An Bras Dermatol.
90:862–867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Maiuolo J, Oppedisano F, Gratteri S,
Muscoli C and Mollace V: Regulation of UA metabolism and excretion.
Int J Cardiol. 213:8–14. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Coimbra S and Santos-Silva A: Biomarkers
of psoriasis severity and therapy monitoring. World J Dermatol.
3:15–27. 2014. View Article : Google Scholar
|
|
55
|
Yıldırım FE, Karaduman A, Pinar A and
Aksoy Y: CD26/ dipeptidyl-peptidase IV and adenosine deaminase
serum levels in psoriatic patients treated with cyclosporine,
etanercept, and psoralen plus ultraviolet A phototherapy. Int J
Dermatol. 50:948–955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Bukulmez G, Akan T and Ciliv G: Serum
adenosine deaminase levels in patients with psoriasis: A
prospective case-control study. Eur J Dermatol. 10:274–276.
2000.PubMed/NCBI
|
|
57
|
Nicolae I, ENE CD, Georgescu SR, Tampa M,
Matei C and Ceausu E: Effects of UV radiation and oxidative DNA
adduct 8-hydroxy-2′-deoxiguanosine on the skin diseases. Rev Chim.
65:1036–1041. 2014.
|
|
58
|
Birben E, Sahiner UM, Sackesen C, Erzurum
S and Kalayci O: Oxidative stress and antioxidant defense. World
Allergy Organ J. 5:9–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Remuzzi G and Bertani T: Pathophysiology
of progressive nephropathies. N Engl J Med. 339:1448–1456. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tsai JP, Liou JH, Yeh KT, Tai HC, Cheng YW
and Chang HR: Intensity of cytosol expression of 8-OHdG in normal
renal tubules is associated with the severity of renal fibrosis.
Swiss Med Wkly. 141:w132682011.PubMed/NCBI
|
|
61
|
Dincer Y, Sekercioglu N, Pekpak M, Gunes
KN and Akcay T: Assessment of DNA oxidation and antioxidant
activity in hypertensive patients with chronic kidney disease. Ren
Fail. 30:1006–1011. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Domenici FA, Vannucchi MT, Jordão AA Jr,
Meirelles MS and Vannucchi H: DNA oxidative damage in patients with
dialysis treatment. Ren Fail. 27:689–694. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shah SV, Baliga R, Rajapurkar M and
Fonseca VA: Oxidants in chronic kidney disease. J Am Soc Nephrol.
18:16–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY
and Lim SJ: Effects of sildenafil on oxidative and inflammatory
injuries of the kidney in streptozotocin-induced diabetic rats. Am
J Nephrol. 29:274–282. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Akçay T, Saygili I, Andican G and Yalçin
V: Increased formation of 8-hydroxy-2′-deoxyguanosine in peripheral
blood leukocytes in bladder cancer. Urol Int. 71:271–274. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Miyake H, Hara I, Kamidono S and Eto H:
Prognostic significance of oxidative DNA damage evaluated by
8-hydroxy-2′-deoxyguanosine in patients undergoing radical
nephrectomy for renal cell carcinoma. Urology. 64:1057–1061. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chang CH, Yang CM and Yang AH: Renal
diagnosis of chronic hemodialysis patients with urinary tract
transitional cell carcinoma in Taiwan. Cancer. 109:1487–1492. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tatu AL and Nwabudike LC:
Metoprolol-associated onset of psoriatic arthropathy. Am J Ther.
24:e370–e371. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Namazi MR: Cannabinoids, loratadine and
allopurinol as novel additions to the antipsoriatic ammunition. J
Eur Acad Dermatol Venereol. 19:319–322. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tsuruta N, Imafuku S and Narisawa Y:
Hyperuricemia is an independent risk factor for psoriatic arthritis
in psoriatic patients. J Dermatol. 44:1349–1352. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Merola JF, Wu S, Han J, Choi HK and
Qureshi AA: Psoriasis, psoriatic arthritis and risk of gout in US
men and women. Ann Rheum Dis. 74:1495–1500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Singh NP, Prakash A, Kubba S, Ganguli A,
Singh AK, Sikdar S, Agarwal SK, Dinda AK and Grover C: Psoriatic
nephropathy - does an entity exist? Ren Fail. 27:123–127. 2005.
View Article : Google Scholar : PubMed/NCBI
|
